Meetings and Publications

17th Annual Discovery on Target 2019, Boston, MA, September 17-19, 2019

A Novel RORγ Antagonist Exhibits Excellent Topical Efficacy in Preclinical Animal Models for Psoriasis

Read more

Gordon Research Conference Nucleosides, Nucleotides and Oligonucleotides, Newport, RI, June 23-28, 2019

Discovery of Polyaza Macrocycles and Bispyridines as CD73 Inhibitors

Read more

255th ACS National Meeting, New Orleans, LA, March 18-22, 2018

Discovery of Furanone Derivatives as Potent BRAF Inhibitors

Read more

Feb, 2018 - Publication

Discovery of EBI-1051: A novel and orally efficacious MEK inhibitor with benzofuran scaffold

Read More

Jan, 2018 - Publication

Discovery of EBI-2511: A highly potent and orally active EZH2 inhibitor for the treatment of Non-Hodgkin’s lymphoma

Read More

Feb, 2016 - Publication

Discovery of EBI-907: A highly potent and orally active B-RafV600E inhibitor for the treatment of melanoma and associated cancers

Read More

Feb, 2016 - Publication

EBI-907, a novel BRAFV600E inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile

Read More

AACR Annual Meeting , Philadelphia, PA, April 18-22, 2015

Discovery and pharmacological characterization of the second generation of Btk inhibitors with improved target selectivity and enhanced in vivo efficacy

Read More

248th ACS National Meeting, San Francisco, CA, August 10-14, 2014

Discovery of quinazolinedione derivatives as potent PARP1 inhibitors

Read more

AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics , Boston, MA, October 19-23, 2013

Discovery of a novel and potent BRAF (V600E) inhibitor with a unique kinase targeting profile, EBI-907: pharmacological characterization and strategies to overcome drug resistance and paradoxical activation

Read more